ERBB2 and gastric cancer: Jung discovered that the BVAC-B vaccine (an autologous B-cell-and monocyte-based immunotherapy vaccine) activated immune cells in patients with HER2-positive gastric cancer, although its clinical efficacy was limited, in the treatment of HER2-positive advanced gastric cancer (122).